Cerevel Therapeutics Hldg Analyst Ratings
Cerevel Therapeutics Hldg Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 11.26% | Mizuho | $29 → $25 | Maintains | Neutral |
| 08/03/2023 | 86.92% | Morgan Stanley | $46 → $42 | Maintains | Overweight |
| 08/03/2023 | 37.96% | B of A Securities | $36 → $31 | Downgrades | Buy → Neutral |
| 08/03/2023 | 82.47% | HC Wainwright & Co. | $45 → $41 | Maintains | Buy |
| 05/23/2023 | 33.51% | Goldman Sachs | $31 → $30 | Maintains | Neutral |
| 05/08/2023 | 29.06% | Mizuho | $26 → $29 | Maintains | Neutral |
| 05/04/2023 | 33.51% | Wells Fargo | → $30 | Upgrades | Equal-Weight → Overweight |
| 04/10/2023 | — | TD Cowen | Initiates Coverage On | → Outperform | |
| 04/03/2023 | 100.27% | HC Wainwright & Co. | → $45 | Reiterates | → Buy |
| 03/17/2023 | 29.06% | JP Morgan | $40 → $29 | Downgrades | Overweight → Neutral |
| 03/16/2023 | -2.09% | Berenberg | → $22 | Reinstates | → Hold |
| 03/09/2023 | 15.71% | Mizuho | $28 → $26 | Maintains | Neutral |
| 02/23/2023 | 78.02% | Morgan Stanley | $50 → $40 | Maintains | Overweight |
| 02/23/2023 | 100.27% | HC Wainwright & Co. | $48 → $45 | Maintains | Buy |
| 02/23/2023 | 33.51% | Wells Fargo | $38 → $30 | Downgrades | Overweight → Equal-Weight |
| 02/22/2023 | 37.96% | Goldman Sachs | $28 → $31 | Maintains | Neutral |
| 12/06/2022 | 78.02% | JP Morgan | $49 → $40 | Maintains | Overweight |
| 11/10/2022 | 24.61% | Mizuho | $32 → $28 | Maintains | Neutral |
| 11/09/2022 | 113.62% | HC Wainwright & Co. | $50 → $48 | Maintains | Buy |
| 11/01/2022 | 78.02% | Loop Capital | → $40 | Initiates Coverage On | → Buy |
| 10/20/2022 | 73.56% | B of A Securities | → $39 | Initiates Coverage On | → Buy |
| 09/29/2022 | 82.47% | Cantor Fitzgerald | → $41 | Initiates Coverage On | → Overweight |
| 09/26/2022 | 69.11% | Wells Fargo | → $38 | Initiates Coverage On | → Overweight |
| 09/21/2022 | 24.61% | Goldman Sachs | $24 → $28 | Maintains | Neutral |
| 09/13/2022 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 08/23/2022 | 42.41% | Mizuho | $27 → $32 | Maintains | Neutral |
| 08/22/2022 | 122.52% | Morgan Stanley | $39 → $50 | Maintains | Overweight |
| 08/09/2022 | 140.32% | Stifel | $50 → $54 | Maintains | Buy |
| 08/03/2022 | 20.16% | Mizuho | $30 → $27 | Maintains | Neutral |
| 07/07/2022 | 33.51% | Mizuho | → $30 | Initiates Coverage On | → Neutral |
| 05/24/2022 | -10.99% | Goldman Sachs | $28 → $20 | Maintains | Neutral |
| 02/15/2022 | 20.16% | Goldman Sachs | → $27 | Initiates Coverage On | → Neutral |
| 01/05/2022 | 122.52% | JP Morgan | → $50 | Initiates Coverage On | → Overweight |
| 12/16/2021 | 122.52% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 09/07/2021 | 73.56% | Morgan Stanley | $27 → $39 | Maintains | Overweight |
| 06/18/2021 | 20.16% | Morgan Stanley | → $27 | Initiates Coverage On | → Overweight |
| 12/10/2020 | 6.81% | Goldman Sachs | → $24 | Initiates Coverage On | → Buy |
| 11/23/2020 | -19.89% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 11/09/2020 | -24.34% | Stifel | → $17 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/07/2023 | 11.26% | 瑞穗 | $29→$25 | 维护 | 中性 |
| 08/03/2023 | 86.92% | 摩根士丹利 | $46→$42 | 维护 | 超重 |
| 08/03/2023 | 37.96% | B of A证券 | $36→$31 | 评级下调 | 购买→中性 |
| 08/03/2023 | 82.47% | HC Wainwright公司 | $45→$41 | 维护 | 买 |
| 2023年05月23日 | 33.51% | 高盛 | $31→$30 | 维护 | 中性 |
| 05/08/2023 | 29.06% | 瑞穗 | $26→$29 | 维护 | 中性 |
| 05/04/2023 | 33.51% | 富国银行 | →$30 | 升级 | 等重→超重 |
| 04/10/2023 | - | TD Cowen | 开始承保 | →跑赢大盘 | |
| 04/03/2023 | 100.27% | HC Wainwright公司 | →$45 | 重申 | →购买 |
| 03/17/2023 | 29.06% | 摩根大通 | $40→$29 | 评级下调 | 超重→中性 |
| 03/16/2023 | -2.09% | 贝伦伯格 | →$22 | 恢复 | →保留 |
| 03/09/2023 | 15.71% | 瑞穗 | $28→$26 | 维护 | 中性 |
| 02/23/2023 | 78.02% | 摩根士丹利 | $50→$40 | 维护 | 超重 |
| 02/23/2023 | 100.27% | HC Wainwright公司 | $48→$45 | 维护 | 买 |
| 02/23/2023 | 33.51% | 富国银行 | $38→$30 | 评级下调 | 超重→等重 |
| 02/22/2023 | 37.96% | 高盛 | $28→$31 | 维护 | 中性 |
| 12/06/2022 | 78.02% | 摩根大通 | $49→$40 | 维护 | 超重 |
| 2022年11月10日 | 24.61% | 瑞穗 | $32→$28 | 维护 | 中性 |
| 11/09/2022 | 113.62% | HC Wainwright公司 | $50→$48 | 维护 | 买 |
| 11/01/2022 | 78.02% | 环路资本 | →$40 | 开始承保 | →购买 |
| 10/20/2022 | 73.56% | B of A证券 | →$39 | 开始承保 | →购买 |
| 09/29/2022 | 82.47% | 康托·菲茨杰拉德 | →$41 | 开始承保 | →超重 |
| 09/26/2022 | 69.11% | 富国银行 | →$38 | 开始承保 | →超重 |
| 2022/09/21 | 24.61% | 高盛 | $24→$28 | 维护 | 中性 |
| 09/13/2022 | - | Evercore ISI集团 | 开始承保 | →跑赢大盘 | |
| 2022年08月23日 | 42.41% | 瑞穗 | $27→$32 | 维护 | 中性 |
| 2022/08/22 | 122.52% | 摩根士丹利 | $39→$50 | 维护 | 超重 |
| 08/09/2022 | 140.32% | Stifel | $50→$54 | 维护 | 买 |
| 08/03/2022 | 20.16% | 瑞穗 | $30→$27 | 维护 | 中性 |
| 07/07/2022 | 33.51% | 瑞穗 | →$30 | 开始承保 | →中性 |
| 2022年05月24日 | -10.99% | 高盛 | $28→$20 | 维护 | 中性 |
| 02/15/2022 | 20.16% | 高盛 | →$27 | 开始承保 | →中性 |
| 01/05/2022 | 122.52% | 摩根大通 | →$50 | 开始承保 | →超重 |
| 12/16/2021 | 122.52% | HC Wainwright公司 | →$50 | 开始承保 | →购买 |
| 09/07/2021 | 73.56% | 摩根士丹利 | $27→$39 | 维护 | 超重 |
| 06/18/2021 | 20.16% | 摩根士丹利 | →$27 | 开始承保 | →超重 |
| 12/10/2020 | 6.81% | 高盛 | →$24 | 开始承保 | →购买 |
| 11/23/2020 | -19.89% | 杰富瑞 | →$18 | 开始承保 | →购买 |
| 11/09/2020 | -24.34% | Stifel | →$17 | 开始承保 | →购买 |
What is the target price for Cerevel Therapeutics Hldg (CERE)?
Cerevel Treateutics Hldg(CERE)的目标价格是多少？
The latest price target for Cerevel Therapeutics Hldg (NASDAQ: CERE) was reported by Mizuho on August 7, 2023. The analyst firm set a price target for $25.00 expecting CERE to rise to within 12 months (a possible 11.26% upside). 28 analyst firms have reported ratings in the last year.
瑞穗于2023年8月7日报道了Cerevel Treateutics Hldg(纳斯达克：CEE)的最新目标价。这家分析公司将目标价定为25美元，预计CERE将在12个月内升至(可能上涨11.26%)。去年有28家分析公司公布了评级。
What is the most recent analyst rating for Cerevel Therapeutics Hldg (CERE)?
Cerevel Treateutics Hldg(CERE)最近的分析师评级是什么？
The latest analyst rating for Cerevel Therapeutics Hldg (NASDAQ: CERE) was provided by Mizuho, and Cerevel Therapeutics Hldg maintained their neutral rating.
瑞穗提供了对Cerevel Treateutics Hldg(纳斯达克代码：CEE)的最新分析师评级，Cerevel Treateutics Hldg维持其中性评级。
When is the next analyst rating going to be posted or updated for Cerevel Therapeutics Hldg (CERE)?
Cerevel Treateutics Hldg(CERE)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cerevel Therapeutics Hldg, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cerevel Therapeutics Hldg was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Cerevel Treateutics Hldg的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Cerevel Treateutics Hldg的上一次评级是在2023年8月7日提交的，因此您应该预计下一次评级将在2024年8月7日左右提供。
Is the Analyst Rating Cerevel Therapeutics Hldg (CERE) correct?
分析师对Cerevel Treateutics Hldg(CERE)的评级正确吗？
While ratings are subjective and will change, the latest Cerevel Therapeutics Hldg (CERE) rating was a maintained with a price target of $29.00 to $25.00. The current price Cerevel Therapeutics Hldg (CERE) is trading at is $22.47, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Cerevel Treateutics Hldg(CERE)评级保持不变，目标价在29.00美元至25.00美元之间。Cerevel Treateutics Hldg(CERE)目前的交易价格为22.47美元，超出了分析师的预测范围。